man immunodeficiency virus infection [23]. Laboratory findings of his serum showed a few curious values. One was that HBeAg was detected in his serum in spite of a stop codon existing in the precore region of its genome, generally aborting the production of HBeAg at the stage of translation. Stuyver et al. also observed the same phenomenon, detection of HBeAg despite the stop codon in the precore region, and speculated that HBV/G might harbor another mechanism for producing HBeAg. Two years later, the mystery was solved by demonstration of coinfection with HBV/A in four of four sera with HBV/G [6]. It was explained that the HBeAg in the sera was produced by the coinfected precore wild type HBV/A. Furthermore, it was revealed that eight of the eight HBV/G patients from San Francisco were coinfected with HBV/A [7], and three of the three HBV/G patients were coinfected with HBV/A, or HBV/A and HBV/C in Canada [10]. These findings of the high frequency of coinfection of HBV/G with other genotypes give rise to another question, of whether HBV/G is competent to replicate by itself. An inoculation experiment in chimpanzees or an expression study in cultured cells would be required to answer this question.

The entire genome sequence of HBV/G has been reported from France [4,24], the USA [22], and Germany [8] so far. Interestingly, the sequence homology of these strains was surprisingly high. In one study in the USA, 10 HBV/G isolates, including 8 from San Francisco as well as 2 from France (FR1 [4] and B1-89 [24]), had a sequence homology of 99.3–99.8% among themselves [22]. Furthermore, another report from Germany showed that the HBV/G isolate (235/01) was nearly identical (sequence homology of the entire length was 99.7%) to both B1-89 and FR1 [8]. There are a few possible explanations for this finding. One possibility is that there are epidemiological links among French, German, and American HBV/G. A patient with HBV/G from Germany [8] and a homosexual male patient with HBV/G from San Francisco [23] were both positive for human immunodeficiency virus type-1. Thus, HBV/G might spread among a specific population, such as homosexual men or intravenous drug users. This would be also associated with the fact that HBV/G was not found among the patients in the current study, in which homosexual and intravenous drug were not included. The other possibilities are that HBV/G has a high genetic stability or was introduced into humans very recently. The mutation rate of HBV has been estimated to be 4.57×10^{-5} per site per year [25]. Thus, HBV/G might have an exceptionally low mutation rate under specific conditions, or the time since its introduction into humans might not have been long enough to gain a genetic diversity like that of the other six genotypes. To elucidate this issue, more HBV/G isolates from a wide variety of areas should be investigated.

In conclusion, HBV/G was investigated in a large cohort of patients with HBV from various areas in Japan, but no HBV/G isolate was identified, in either single or dual infection. The finding of the current nationwide study, the same as that of the previous study investigated the patients in a restricted area, indicates that HBV/G is extremely rare in Japan. Further studies with a large sample size from various areas in the world are required to further reveal the virological and clinical characteristics of HBV/G.

Acknowledgements

Dr. Masashi Mizokami was given a Grant by the Ministry of Health, Labor, and Welfare of Japan (H13-kaken-2).

References

[1] Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733–45.
[2] Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988;69:2575–83.
[3] Norder H, Ebert JW, Fields HA, Mushahwar IK, Magnius LO. Complete sequencing of a gibbon hepatitis B virus genome reveals a unique genotype distantly related to the chimpanzee hepatitis B virus. Virology 1996;218:214–23.
[4] Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67–74.
[5] Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003;46:329–38.
[6] Kato H, Orito E, Gish RG, et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology 2002;35:922–9.
[7] Kato H, Gish RG, Bzowej N, et al. Eight genotypes (A–H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. J Med Virol 2004;73:516–21.
[8] Vieth S, Manegold C, Drosten C, Nippraschk T, Gunther S. Sequence and phylogenetic analysis of hepatitis B virus genotype G isolated in Germany. Virus Genes 2002;24:153–6.
[9] Sanchez LV, Maldonado M, Bastidas-Ramirez BE, Norder H, Panduro A. Genotypes and S-gene variability of Mexican hepatitis B virus strains. J Med Virol 2002;68:24–32.
[10] Osiowy C, Giles E. Evaluation of the INNO-LiPA HBV genotyping assay for determination of hepatitis B virus genotype. J Clin Microbiol 2003;41:5473–7.
[11] Orito E, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001;34:590–4.
[12] Joh R, Hasegawa K, Ogawa M, et al. Genotypic analysis of hepatitis B virus from patients with fulminant hepatitis: comparison with acute self-limited hepatitis. Hepatol Res 2003;26:119–24.
[13] Lin ZM, Yatsuhashi H, Daikoku M, et al. Hepatitis B virus of genotype C persistence after recovery from acute hepatitis B virus infection in Japan. Hepatol Res 2003;25:244–53.
[14] Kato H, Orito E, Sugauchi F, et al. Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. J Virol Meth 2001;98:153–9.
[15] Mizokami M, Nakano T, Orito E, et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999;450:66–71.
[16] Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554–9.
[17] Orito E, Mizokami M, Sakugawa H, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001;33:218–23.

[18] Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848–56.
[19] Kato H, Orito E, Sugauchi F, et al. Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. J Virol Meth 2003;110:29–35.
[20] Sugauchi F, Orito E, Ichida T, et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002;76:5985–92.
[21] Sugauchi F, Orito E, Ichida T, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003;124:925–32.
[22] Kato H, Orito E, Gish RG, et al. Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). J Virol 2002;76:6131–7.
[23] Bhat RA, Ulrich PP, Vyas GN. Molecular characterization of a new variant of hepatitis B virus in a persistently infected homosexual man. Hepatology 1990;11:271–6.
[24] Tran A, Kremsdorf D, Capel F, et al. Emergence of and takeover by hepatitis B virus (HBV) with rearrangements in the pre-S/S and pre-C/C genes during chronic HBV infection. J Virol 1991;65:3566–74.
[25] Orito E, Mizokami M, Ina Y, et al. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci USA 1989;86:7059–62.

Journal of Medical Virology 75:235–239 (2005)

Quantitative Detection of Hepatitis B Surface Antigen by Chemiluminescent Microparticle Immunoassay During Lamivudine Treatment of Chronic Hepatitis B Virus Carriers

Madoka Kohmoto,[1] Masaru Enomoto,[1] Akihiro Tamori,[1] Daiki Habu,[1] Tadashi Takeda,[1] Norifumi Kawada,[1] Hiroki Sakaguchi,[1] Shuichi Seki,[1] Susumu Shiomi,[2] and Shuhei Nishiguchi[1]*

[1]*Department of Hepatology, Osaka City University Medical School, Abeno-ku, Osaka, Japan*
[2]*Department of Nuclear Medicine, Osaka City University Medical School, Abeno-ku, Osaka, Japan*

The usefulness of fully automated chemiluminescent microparticle immunoassay (Architect HBsAg QT) for monitoring serum levels of hepatitis B virus (HBV) during antiviral therapy remains unclear. Using this assay, hepatitis B surface antigen (HBsAg) was measured in 20 patients with chronic hepatitis B before and during lamivudine treatment. At the start of therapy, 12 patients had detectable hepatitis B e antigen (HBeAg) and 8 did not. The median serum HBV DNA level and HBsAg concentration (25th–75th centile) were 7.2 (6.1–7.8) log genome equivalents/ml and 3,932 (1,585–12,330) IU/ml, respectively. The HBsAg concentration was significantly higher in HBeAg positive than in HBeAg negative patients ($P = 0.031$). There was a significant correlation between the HBsAg concentration and HBV DNA level ($r = 0.490$, $P = 0.027$). The HBsAg concentration negatively correlated with patient age ($r = -0.395$, $P = 0.085$). After the start of lamivudine therapy, HBV DNA levels fell rapidly in all patients. Serum HBsAg concentrations also fell in most patients, but to a lesser extent. When drug-resistant variants emerged, serum HBsAg usually increased before biochemical breakthrough. Although HBV DNA was elevated persistently after the emergence of drug-resistant variants, the increase in HBsAg was transient. In some patients, the increase in HBsAg preceded the increase in HBV DNA. Monitoring of serum HBsAg concentrations with the use of Architect HBsAg QT, in addition to measurement of HBV DNA levels, is helpful for evaluating the response to lamivudine treatment and for the early detection of drug-resistant strains. ***J. Med. Virol. 75:235–239, 2005.*** © 2004 Wiley-Liss, Inc.

KEY WORDS: HBsAg; HBV; HBV mutants; hepatitis B virus; YMDD variants; lamivudine therapy

© 2004 WILEY-LISS, INC.

INTRODUCTION

Hepatitis B virus (HBV) is the major cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. It is estimated that more than 350 million people worldwide are chronically infected with this virus [Lee, 1997]. Lamivudine, the first safe oral nucleoside analogue for the treatment of chronic hepatitis B, is now used widely. This compound suppresses effectively viral replication and prevents the progression of chronic liver disease [Lai et al., 1998; Dienstag et al., 1999; Lau et al., 2000]. However, prolonged treatment with lamivudine induces the emergence of variants with mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the HBV polymerase gene. These mutants are resistant to lamivudine and can cause virological and/or biochemical breakthrough during therapy [Ling et al., 1996; Tipples et al., 1996]. It is therefore imperative that serum levels of hepatitis B e antigen (HBeAg) and HBV DNA are measured during lamivudine treatment to monitor the response to therapy and facilitate the early detection of drug-resistant strains [Kohmoto et al., 2003].

A simple and inexpensive method with a wide detection range is required for frequent measurement of serum HBV levels during antiviral treatment. Serum HBeAg, anti-HBe, and HBV DNA are currently the most important markers for assessing the response to lamivudine therapy. In contrast, HBsAg is used typically as a qualitative serological marker for diagnosing the presence of acute or chronic HBV infection. A fully

Grant sponsor: Ministry of Health, Labour and Welfare, Japan.

*Correspondence to: Shuhei Nishiguchi, Department of Hepatology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
E-mail: snishiguch@med.osaka-cu.ac.jp

Accepted 27 September 2004
DOI 10.1002/jmv.20262
Published online in Wiley InterScience
(www.interscience.wiley.com)

automated chemiluminescent microparticle immunoassay (Architect HBsAg QT) for the quantitative detection of HBsAg has recently been introduced [Coleman et al., 1999; Deguchi et al., 2004]. Architect HBsAg QT can test many samples simultaneously in a short time and measure HBsAg concentrations over a wide detection range. However, the utility of this assay as a serological marker during lamivudine treatment has not yet been evaluated using clinical samples.

The aim of this study was to evaluate the Architect HBsAg QT as a method for monitoring viral loads during lamivudine treatment. Using this method, we measured HBsAg concentrations in patients with chronic HBV infection who received lamivudine. Changes in HBsAg concentrations were compared with those in HBV DNA before and after the emergence of YMDD variants.

MATERIALS AND METHODS

Patients

The subjects were 20 patients with chronic HBV infection (16 men and 4 women; mean age: 46 ± 12 years) who had received lamivudine between May 1995 and May 2003. The inclusion criteria were as follows: (1) persistent or fluctuating elevations of serum alanine aminotransferase (ALT) levels before therapy; (2) presence of HBsAg in serum; (3) presence of HBV DNA detectable by polymerase chain reaction (PCR); (4) absence of antibodies to hepatitis C virus and other likely causes of chronic liver disease; (5) no known use of corticosteroids, immunosuppressant drugs, or antiviral agents within 1 year before the start of therapy; and (6) no clinical signs of decompensated cirrhosis or hepatocellular carcinoma. Lamivudine was given orally at a dosage of 100 mg once daily for 12–18 months. Serum samples were obtained from the patients immediately before the start of therapy and at intervals of 1–2 months during therapy. Informed consent was obtained from all patients. Experimental procedures were in accordance with the Helsinki Declaration of 1975 (1983 revision) and were approved by the ethics committee of our hospital.

Routine Laboratory Tests

The following assays were done for all enrolled patients at the start of therapy: serum ALT activity, HBeAg, anti-HBe, and HBV DNA. Serum ALT was measured with an Autoanalyzer 7450 (Hitachi, Tokyo, Japan). HBeAg and anti-HBe were detected by radioimmunoassay. HBV DNA was measured by transcription-mediated amplification (TMA) with a hybridization protection assay (Chugai Diagnostics, Tokyo, Japan) as described elsewhere [Kamisango et al., 1999; Ide et al., 2001]. The detection range of this assay was between 3.7 and 8.7 log genome equivalents (LGE)/ml.

Quantitation of HBsAg

All serum samples were tested for HBsAg using the Architect HBsAg QT (Abbott Japan Corp., Tokyo) according to the manufacturer's protocol. Briefly, in the first step, the sample and anti-HBs-coated paramagnetic microparticles are combined. If HBsAg is present in the sample, it binds to the anti-HBs-coated microparticles. After washing, an acridinium-labeled anti-HBs conjugate is added. Following another wash cycle, pre-trigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured in relative light units. The amount of HBsAg in the sample is related directly to the relative light units detected by Architect HBsAg QT. Architect HBsAg QT is capable of measuring a wide range, from 0.05 to 250 IU/ml. Samples with an HBsAg level higher than 250 IU/ml require a 1:500 or greater dilution to bring them into the range of the calibration curve.

Detection of YMDD Mutant Strains

Mutations in the YMDD motif of the polymerase gene were examined by a line probe assay (INNO-LiPA HBV DR, Innogenetics NV, Belgium) [Stuyver et al., 2000] for patients who had a significant increase in HBV DNA during lamivudine treatment.

Statistical Analysis

Statistical analysis was performed with the use of the Statview SE + Graphics program, version 5.0 (SAS Institute, Cary, NC). The significance of correlations was evaluated by Spearman's rank analysis. Distributions of continuous variables were analyzed by the Mann–Whitney *U*-test. A two-tailed *P* value of less than 0.05 was considered to indicate statistical significance.

RESULTS

Baseline Characteristics of Patients

Among the 20 enrolled patients with chronic HBV infection, 12 had detectable HBeAg and 8 had undetectable HBeAg at the start of lamivudine therapy. The median serum ALT level, HBV DNA level, and HBsAg concentration (25th–75th centile) were 88 (59–220) IU/L, 7.2 (6.1–7.8) LGE/ml, and 3,932 (1,585–12,330) IU/ml, respectively.

Relations Between HBsAg Concentrations and Other Clinical Variables

The relations between concentrations of HBsAg and those of the other serological markers at the start of lamivudine therapy are shown in Figure 1. The HBsAg concentration was significantly higher in patients with detectable HBeAg than in patients without HBeAg ($P = 0.031$). When a value of 3.7 LGE/ml was assigned to HBV DNA levels below the lower detection limit of the TMA assay for calculation purposes, a significant correlation was obtained between measurements of HBsAg and of HBV DNA ($r = 0.490$, $P = 0.027$). The relation between the HBsAg concentrations and the ages of the patients at the start of therapy is shown in Figure 2. The HBsAg concentration negatively corre-



Fig. 1. A: Difference in hepatitis B surface antigen (HBsAg) concentrations between patients with and without detectable HBeAg at the start of lamivudine treatment. B: Correlation between serum HBsAg concentrations and serum hepatitis B virus (HBV) DNA levels measured at the start of therapy. The broken line indicates the detection limits of the assay.



Fig. 2. Relation between HBsAg concentrations and age of patients at the start of lamivudine treatment.

lated with patient age, although the correlation was not statistically significant ($r = -0.395$, $P = 0.085$).

Changes in HBsAg and HBV DNA During Lamivudine Therapy

Changes in median HBsAg concentrations and median HBV DNA levels during the first 6 months of lamivudine therapy are shown in Figure 3. After lamivudine therapy commenced, HBV DNA levels fell rapidly in all patients. Serum HBsAg concentrations also fell in most patients, but the decrease in HBsAg was smaller and more gradual. HBsAg was detected during therapy in all patients.

Case Reports

YMDD mutant variants emerged in 12 patients between months 5 and 14 of therapy. The clinical courses of two patients with YMDD variants are shown in Figure 4. The first patient, a 45-year-old man, had received lamivudine since December 2001. At the start of therapy, HBeAg was positive. HBV DNA and HBsAg levels declined after the start of therapy. At month 8 of therapy, viral breakthrough associated with emergence of YMDD variants occurred. Increased serum HBV DNA and HBsAg levels were observed before biochemical breakthrough. After YMDD variants emerged, serum HBV DNA was persistently elevated, whereas the increase in HBsAg was transient.

The second patient, a 34-year-old man, participated in Japanese phase III clinical trials of lamivudine in 1995 and received 48 weeks of treatment. HBeAg was positive at the start of therapy. A liver biopsy specimen showed moderate inflammation and moderate fibrosis. After the start of therapy, there was a significant decline in HBV DNA, but the HBsAg level did not decrease. At month 7 of therapy, HBsAg was markedly elevated, with no significant increase in HBV DNA. About 4 months subsequently, a breakthrough in ALT activity associated with YMDD variants occurred.

DISCUSSION

Monitoring of HBeAg and HBV DNA levels in serum is important for assessing the response to antiviral treatment. However, because of the possible presence of HBeAg negative variants with mutations in the precore or basic core promoter region among some chronic HBV carriers, it is difficult to correlate the absence of HBeAg with the level of HBV replication. Several assays for serum HBV DNA are available commercially: the branched DNA signal amplification assay [Jen et al., 2001], TMA assay [Kamisango et al., 1999; Ide et al., 2001], and PCR-based assays [Gerken et al., 1998]. The branched DNA assay is based on the hybridization of HBV DNA to oligonucleotide probes. This assay is not sensitive enough to measure low serum HBV levels during antiviral therapy. TMA assay and PCR-based nucleic acid amplification tests have been developed to provide more sensitive, quantitative methods for the detection of HBV DNA. However, these methods involve cumbersome procedures and high costs, and generate divergent results.



Fig. 3. Changes in HBsAg concentrations (●) and in HBV DNA levels (○) during the first 6 months of lamivudine therapy. Values are medians, with bars showing the 25th–75th centile.

In this study, the Architect HBsAg QT was used to monitor HBsAg concentrations during lamivudine treatment. This method measures HBsAg with high intra-assay precision and inter-assay reproducibility over a wide detection range. The lower limit of detection was 0.05 IU/ml, which is equivalent or superior to that of other commercially available immunoassays. Coleman et al. [1999] reported that several known HBV vaccine-escape variants with mutations in the "a" determinant within the hydrophilic region of HBsAg are detected by this assay. The Architect HBsAg QT is a simple, sensitive, specific, reproducible, and inexpensive method that produces results rapidly and accurately. The wide detection range of this method is



Fig. 4. Clinical courses of two patients (A), a 45-year-old man and (B), a 34-year-old man. ●, HBsAg concentration; ■, HBV DNA level. ▲, ALT activity. YMDD, tyrosine-methionine-aspartate-aspartate.

appropriate for assessment of response to antiviral therapy, and the low cost of the assay permits frequent testing of serum samples.

Many elderly patients have undetectable HBeAg levels and low titers of HBV DNA. In our study, the serum HBsAg concentration was lower in elderly patients than in younger patients. The age-related decrease in serum HBsAg levels may be due to low viral replication. Fan et al. [2001] reported that the frequency of deletion mutants in the pre-S region of HBV DNA is increased in patients with low viral replication and proposed that several pre-S deletion mutants cause a remarkable decrease in the synthesis and secretion of small surface antigens. The emergence of the pre-S deletion mutants may also be related to the decrease in HBsAg levels in the elderly.

A positive correlation was found between HBsAg and HBV DNA levels before lamivudine treatment. Early in the course of therapy, changes in HBsAg concentrations appeared to correlate with changes in HBV DNA levels. However, the decrease in HBsAg was much smaller than that in HBV DNA during lamivudine treatment. Kimura et al. [2003] reported that the decrease in hepatitis B core antigen (HBcAg) level as measured by a sensitive enzyme immunoassay was also smaller than that in the HBV DNA level during therapy. One possible explanation for these differences is that covalently closed circular DNA (cccDNA) may continue to remain in hepatocytes during lamivudine treatment. Lamivudine strongly inhibits HBV reverse transcriptase and HBV DNA production, but has little or no effect on cccDNA [Lee, 1997]. Consequently, viral proteins such as HBsAg or HBcAg might be persistently translated and released into the circulation, even during therapy.

When YMDD mutant variants emerged, an increase in serum HBsAg concentrations as well as in HBV DNA was usually observed before biochemical breakthrough. Although serum HBV DNA was persistently elevated after the emergence of YMDD variants, the increase in HBsAg was transient, similar to the elevation of ALT activity (Fig. 4A). We speculate that the release of HBsAg into serum from hepatocytes might be associated in part with the lysis of hepatocytes involved in the replication of YMDD variants and liver inflammation. Further studies are needed to test this hypothesis. In most patients, the increase in serum HBsAg was preceded by an increase in HBV DNA. In some, however, serum HBsAg increased a few months before the increase in HBV DNA (Fig. 4B). Monitoring of serum HBsAg concentrations in addition to HBV DNA levels may thus facilitate the early detection of drug-resistant mutant variants during lamivudine treatment.

In summary, the Architect HBsAg QT measures serum HBsAg concentrations easily and inexpensively. This assay may be useful for monitoring the response to antiviral treatment, which requires the frequent measurement of serological markers. Monitoring changes in HBsAg concentrations during lamivudine treatment may provide useful information on the activity of HBV and the emergence of drug-resistant variants, as well as changes in levels of HBeAg, anti-HBe, and HBV DNA. If possible, the response to lamivudine therapy should be monitored by assessing both serum HBsAg concentrations and serum HBV DNA levels.

ACKNOWLEDGMENTS

We thank Ms. Megumi Kimura, Ms. Ikuyo Nakamachi, and Ms. Seiko Harima for technical assistance. We are thankful to all participants in the trial and to others who contributed in various ways.

REFERENCES

Coleman PF, Chen YC, Mushahwar IK. 1999. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 59:19–24.

Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, Iinuma K, Mushahwar IK. 2004. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 115:217–222.

Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256–1263.

Fan YF, Lu CC, Chen WC, Yao WJ, Wang HC, Chang TT, Lei HY, Shiau AL, Su IJ. 2001. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 33:277–286.

Gerken G, Gomes J, Lampertico P, Colombo M, Rothaar T, Trippler M, Colucci G. 1998. Clinical evaluation and applications of the Amplicor HBV monitor test, a quantitative HBV DNA PCR assay. J Virol Methods 74:155–165.

Ide T, Kumashiro R, Hino T, Murashima S, Ogata K, Koga Y, Sata M. 2001. Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine. Hepatol Res 21:76–84.

Jen CM, Young KC, Cheng PN, Kao AW, Chang TT. 2001. Limitations and improvements of the quantiplex branched-DNA assay in Hepatitis B virus-infected patients receiving lamivudine. J Virol Methods 96:203–210.

Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S. 1999. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J Clin Microbiol 37:310–314.

Kimura T, Rokuhara A, Matsumoto A, Yagi S, Tanaka E, Kiyosawa K, Maki N. 2003. New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA. J Clin Microbiol 41:1901–1906.

Kohmoto M, Enomoto M, Yano Y, Otani S, Minamitani S, Tamori A, Habu D, Takeda T, Shiomi S, Seki S, Arakawa T, Nishiguchi S. 2003. Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: Comparison with three other assays. Hepatol Res 26:125–133.

Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61–68.

Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828–834.

Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337:1733–1745.

Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711–713.

Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R. 2000. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 38:702–707.

Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714–717.

THE AMERICAN JOURNAL OF Gastroenterology

Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus

For Review

Journal:	*American Journal of Gastroenterology*
Manuscript ID:	draft
Manuscript Type:	Original Contribution
Date Submitted by the Author:	n/a
Keywords:	Hepatocellular carcinoma, hepatitis C
Manuscript Section:	Liver

powered by ScholarOne
Manuscript Central™

ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901

Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus

Akihiro Tamori, M.D., Shuhei Nishiguchi, M.D., Susumu Shiomi, M.D., Takehiro Hayashi, M.D., Sawako Kobayashi, M.D., Daiki Habu, M.D., Tadashi Takeda, M.D., Shuichi Seki, M.D., Kazuhiro Hirohashi, M.D., Hiromu Tanaka, M.D., Shoji Kubo, M.D.

Department of Hepatology, Department of Nuclear Medicine, Department of General Medicine and Department of Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

Correspondence to: A. Tamori, Department of Hepatology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan (e-mail: atamori@med.osaka-cu.ac.jp)

For Peer Review

ABSTRACT

OBJECTIVES: Hepatocellular carcinoma (HCC) has been reported in patients in whom hepatitis C virus (HCV) was eliminated by interferon therapy. We examined the pathogenesis of HCC in patients with sustained viral response.

METHODS: Operable HCC developed in 7 of 342 patients cured of HCV infection by interferon monotherapy. No patient abused alcohol or had diabetes mellitus or obesity. Resected specimens of HCC were histologically evaluated. DNA extracted from HCC was examined by polymerase chain reaction to locate hepatitis B virus (HBV) DNA. HBV integration sites in human genome were identified by cassette-ligation-mediated PCR.

RESULTS: HBV DNA was not amplified in serum samples from any of the 7 patients with HCC and was found in liver in 4 patients. In the latter 4 patients, HBV DNA was integrated into the human genome of HCC. In 2 of these patients, covalently closed circular HBV was also detected. The patients with HBV DNA integration were free of HCV for more than 3 years. In 2 of the 3 patients without HBV DNA integration, the surrounding liver showed cirrhosis. The liver of HCC with HBV DNA integration had not progressed to cirrhosis. Three of the 4 tumors with HBV integration had one integration site each, located at chromosomes 11q12, 11q22-23, and 22q11, respectively. The other tumor had two integration sites, situated at chromosomes 11q13 and 14q32. At chromosome 11q12, HBV DNA was integrated into protein-coding genome, the function of which remains unclear.

CONCLUSION: Integrated HBV DNA may play a role in hepatocarcinogenesis after the clearance of HCV by interferon treatment.

For Peer Review

INTRODUCTION

Interferon (IFN) has potent antiviral activity against hepatitis C virus (HCV). Previous studies have shown that IFN can reduce the incidence of hepatocellular carcinoma (HCC) in patients with HCV infection (1-3). After complete eradication of HCV by IFN therapy, HCC was thought to rarely occur (4). Recent studies have shown that HCC develops in 2.5% to 4.2% of such patients (5-7). These patients may have had advanced liver fibrosis at the time of HCV eradication, and subclinical tumors might have already existed in the liver at the end of IFN therapy (8). In some patients, however, HCC might develop from liver without fibrosis several years after the eradication of HCV by IFN. The etiology of such cases of HCC remains obscure. New regimens combining IFN with antiviral drugs can improve the rate of HCV clearance (9, 10). The risk of HCC might increase in patients with chronic hepatitis who have complete responses to IFN therapy. It is important to delineate the features of HCC occurring after elimination of HCV. Occult hepatitis B virus (HBV) infection is defined as the detection of HBV DNA in the serum or liver of patients without hepatitis B surface antigen (11). In patients with chronic hepatitis C, occult HBV coinfection may exacerbate liver disease (12). Occult HBV infection is present in a substantial proportion of patients with HCV infection and has a pro-oncogenic effect (13). In the present study, we examined resected liver specimens to evaluate the role of occult HBV infection in the development of cancer after the clearance of HCV by IFN treatment. We also describe the clinical course of such patients with HCC.

For Peer Review

METHODS

Patients

At our department, 1286 patients with chronic hepatitis C without cirrhosis and without hepatitis B surface antigen (HBsAg) received IFN monotherapy for 24 weeks from 1992 through 2002. In 342 patients, serum HCV RNA disappeared, and alanine aminotransferase activity (ALT) was within the normal range for 6 months after the end of IFN therapy. We are now monitoring 144 of these patients every half year. HCC was diagnosed in 7 patients, 4 of whom were regularly monitored (cases 1, 4, 6 and 7). Seven patients underwent hepatectomy at our hospital. Their clinical characteristics are described in Table 1. No patient had alcohol abuse, drug usage, or diabetes mellitus. All patients had a body mass index of less than 25 kg/m^2. The surrounding liver tissue was pathologically classified according to the criteria proposed by Desmet et al (14).

Detection of HBV DNA in serum and liver

DNA was extracted from 100 μl of serum or 10 μg of liver tissue by means of proteinase K digestion followed by phenol/chloroform extraction, as described previously (15). HBV DNA in serum or in liver was amplified with specific primers for HBX, HBS, and HBC (sequences of the primers shown in Table 2). Amplification was done in a thermal cycler for 35 cycles: 95°C for 30 sec, 55°C for 60 sec, and 72°C for 60 sec in 40 μl of a reaction buffer containing 30 pmol of the two appropriate primers, four deoxynucleotides each at a concentration of 100 mM, PCR buffer, and 2.5 units of Gold Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT). With 2 μl of the first PCR product, a second PCR was done. To examine covalently closed circular HBV (cccHBV) in liver, extracted DNA was amplified with primers P23, 24, 25, and p26 (Table 2). The amplification procedure and primers have been described previously (16).

Detection of integrated HBV DNA in human genome

For Peer Review

We used cassette-ligation-mediated polymerase chain reaction (PCR) to detect HBV DNA integrated into the human genome as described previously (15). Briefly, 10 μg of DNA was digested with *Eco*RI, *Hin*dIII, or *Pst*I and ligated to double-stranded DNA cassettes with compatible ends. The cassette-ligated DNA fragments were used as a template for nested PCR with the cassette- and HBV-specific primers. One microliter of the DNA solution was amplified in 40 μl of a reaction buffer containing 10 pmol of the two appropriate primers, four deoxynucleotides each at a concentration of 100 mM, PCR buffer, and 2.5 units of LATaq polymerase. The amplifications were carried out in a thermal cycler for 33 cycles (45 sec at 94°C, 2 min at 55°C, 2 min at 72°C), followed by final extension for 10 min at 72°C. With 1 μl of the first PCR product, a second PCR was done. Table 2 shows the sequences of the primers used. The amplified cassette-ligated DNA fragments were subcloned and sequenced with a DNA sequencing system (377A, Applied Biosystems, Tokyo). To identify the integrated site of the host genome, we used the GenomeNet (***http://www.genome.ad.jp***) to compare the sequences adjacent to the integrated HBV DNA with the human sequence.

Statistical analysis

Ages, intervals, and tumor sizes in the two groups were compared by Student's *t* test.

For Peer Review

RESULTS

Pathological findings of the resected liver

The 7 liver tumors were diagnosed as 4 poorly differentiated HCC and 3 moderately differentiated HCC (Table 3). The surrounding liver tissues were diagnosed as chronic hepatitis. The stage of liver fibrosis was VI in 2 specimens, II in 3 specimens, and I in 2 specimens. The activity grade was II in 4 specimens and I in 3 specimens. There was no evidence of fat deposits in any of the specimens.

HBV DNA in serum

HBV DNA was not detected in serum of any of the 7 patients with HCC.

HBV DNA in liver

We detected HBV DNA in 5 of the 7 HCC and 3 of 5 noncancerous liver samples (Figure 1). In detail, HBx was detected in 3 of the 7 tumors and 1 specimen of noncancerous liver tissue. HBc was detected in 4 tumors and 3 liver tissues. HBs was detected in 2 tumors and 3 liver tissues. Covalently closed circular HBV was detected in case 2 (both HCC and noncancerous liver) and in case 4 (only liver tissue).

HBV DNA integrated in human genome

Our results provide evidence that HBV DNA was integrated into human genome in 4 of the 7 patients with HCV infection in whom HCC developed after complete responses to interferon therapy (cases 2, 5, 6, and 7). HBV DNA was integrated into chromosome 11q23 in case 2, chromosome 22q11.23-12 in case 5, chromosome 11q12 in case 6, and chromosomes 11q13 and 14q32 in case 7. In case 6, HBV DNA was integrated into protein-coding sequences, hypothetical LOC387771 protein, the function of which remains unclear. HCC developed more than 3 years after clearance of HCV in the patients with HBV DNA integration (Table 4). The interval from HCV eradication to the diagnosis of cancer was significantly longer in HCC with HBV DNA integration than in

For Peer Review

HCC without it. In HCC without HBV DNA integration, noncancerous liver tissue showed cirrhosis. In HCC with HBV DNA integration, the fibrosis stage of liver tissue was 1 or 2.

Clinical courses of the 7 patients

In 4 patients, in whom more than 3 years had elapsed since the clearance of HCV RNA, HBV DNA was integrated into the human genome of HCC. In 2 of the 3 patients without HBV DNA integration, the surrounding liver showed cirrhosis. In contrast, the surrounding liver of HCC with HBV DNA integration did not progress to cirrhosis. Four patients are alive as of this writing. Tumor recurrence has not been detected in 2 of these patients (Figure 2). The other 3 patients have died: 2 died of tumor progression and 1 of a myocardial infarction at operation. There was no correlation between clinical outcome after surgical treatment and HBV DNA integration.

For Peer Review

DISCUSSION

In the present study, HCC developed in 4 (2.8%) of 144 patients who were regularly followed up after complete eradication of HCV by IFN monotherapy. Previous studies showed that HCC developed in 8 (2.2) of 363 patients, 6 (4.2%) of 142 patients, and 27 (2.3%) of 1197 patients with sustained virus responses to IFN (5-7). Our findings are consistent with these results. The interval from the end of IFN therapy to the detection of HCC varied in these reports. In patients with a short interval, HCC most likely existed before the eradication of HCV by IFN. Makiyama et al described the relation between tumor doubling time and the interval to the detection of HCC (7). They estimated that more than 6 years were required for a single tumor cell to proliferate into a tumor measuring 1 cm in diameter. To our knowledge, 11 cases (including 2 in the present study) in which more than 60 months elapsed from the end of IFN therapy to the detection of HCC have been documented (5-7, 17-19). The longest interval between the end of treatment and diagnosis was 103 months, recorded in a patient in our study. HCC with long intervals between therapy and detection developed in noncirrhotic liver, usually not present in HCC with continuous HCV infection, suggesting that other etiologies are responsible for HCC developing a considerable time after the elimination of HCV. Available evidence thus indicates that factors other than chronic HCV infection play a role in the development of HCC detected after the eradication of HCV. This explanation seems more plausible rather than assuming that a tumor present before the start of IFN therapy grew for more than 5 years without being detected by imaging studies, performed at regular intervals.

Few studies have examined the status of HCC in patients without hepatitis B surface antigen (HBsAg) and antibodies to HCV antigen (anti-HCV), so called non-B, non-C patients. Patients with exposure to aflatoxin B1, alcohol addiction, diabetes mellitus,

For Peer Review

primary biliary cirrhosis, and steatohepatitis are considered at high risk for HCC (20-24). However, none of the patients in our study had these conditions. A recent review proposes that occult HBV is a carcinogenic factor, particularly in the absence of other risk factors for HCC (25). Pollicino et al suggested that occult HBV infection is an independent factor for carcinogenesis in patients with chronic hepatitis C (13). In the present study, HBV DNA was found in 4 of 7 cases of HCC, and cccHBV, virus-growing form, was also detected in 2 cases. HBV DNA was not detected in the serum of any patient. Small amounts of HBV, detected only in liver, are unlikely to induce hepatic injury or cause inflammation leading to carcinogenesis. In contrast, hepatocytes with HBV DNA integrated into the genome may be transformed, independently of the amount of HBV present. In our patients with occult HBV infection, HBV DNA was integrated into the human genome of HCC. There was a protein coding sequence near the HBV DNA integration site in 1 of the 4 HCC with HBV DNA integration. In this case, HBV DNA appeared to directly affect protein expression near the integration site. Integrated HBV DNA most likely caused instability of the human genome, without directly activating or disrupting protein function. A recent European study has reported that HCC was not detected for 5 years in patients who had sustained virological responses to interferon monotherapy (26). The relation between HBV and HCC may be affected by patient demographics. Henry et al reported that in an area with a high prevalence of HBV infection, occult HBV infection is common among patients with cryptogenic liver cirrhosis (27). To our knowledge, the annual incidence of HCC is higher in Japanese patients with HCV than that in countries in which HBV infection is rare. Occult HBV coinfection or past HBV infection in patients with HCV may partially account for the different incidences of HCC. We have previously reported that HBV DNA integration induces hepatocarcinogenesis in Japanese patients with HCV (28).

For Peer Review

HBV DNA integration was detected in HCC obtained from the patients with HCV, irrespective of the response to IFN therapy. A history of HCV infection thus seems to increase the risk of HCC in patients with HBV DNA integration.

In conclusion, our findings provide compelling evidence that occult HBV, especially integrated HBV, plays an important role in the development of HCC in patients with HCV eliminated by IFN therapy. Our results confirm the hypothesis that the elimination of HCV by IFN is not the endpoint of therapy for liver disease.

For Peer Review

ACKNOWLEDGMENT

We appreciate Ms Mayumi Shinzaki for her excellent technical assistance. This study was supported by a grant from Osaka city university medical research foundation and the Ministry of Education, Science, Sports, and Culture, Japan.

For Peer Review

REFERENCES

1. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
2. International Interferon- Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998 ;351: 1535-9.
3. Yoshida H, Tateishi R, Arakawa Y, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425-0.
4. Coverdale SA, Khan MH, Byth K, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004;99:636-44.
5. Toyoda H, Kumada T, Tokuda A, et al. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J Viral Hepat. 2000;7:414-9.
6. Enokimura N, Shiraki K, Kawakita T, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res. 2003; 23: 593-6.
7. Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004;101:1616-22.
8. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study

For Peer Review